• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Wolfe Laboratories adds Paul Oakley as SVP and general counsel

Wolfe Laboratories adds Paul Oakley as SVP and general counsel

May 20, 2016
CenterWatch Staff

Wolfe Laboratories has expanded its senior management team through the addition of Paul Oakley, who has joined as senior vice president and general counsel. In this role, Oakley will be responsible for the company’s corporate and financial strategies and general operations. Oakley brings more than 20 years of experience as an executive and entrepreneur, building and managing high-growth, mission-oriented teams and organizations, as well as an external general counsel for a vast portfolio of emerging growth companies.

“Paul is a tremendous addition to our team. He brings uniquely integrated business, legal and strategic perspectives which will be invaluable in helping us navigate during this time of rapid growth,” said Janet Wolfe, president and CEO of Wolfe Laboratories and to whom Mr. Oakley will be reporting. “With the tremendous demand for integrated pharmaceutical development services, Paul is arriving at the perfect time to lead and optimize our business and operational strategies, ensuring we capitalize on the considerable opportunities before us.”

Prior to joining Wolfe, Oakley served as chief administrative officer for Truelight, an innovative energy firm engaged in short-term trading in the wholesale electricity markets through its proprietary hedge fund, TrueLight Energy Fund. He was also responsible for delivering analytics and business intelligence solutions to the $78B-and-growing competitive retail electricity supply sector and to the multi-billion-dollar clean energy development community through its subsidiary, TrueLight Energy.

“I am delighted to join Wolfe, particularly at this important moment in the company’s development, which is advancing rapidly,” said Oakley. “Wolfe’s integrated pharmaceutical development services for small molecules, biologics and complex molecules, and its key location in Boston’s thriving biopharma ecosystem, provides significant opportunities for value creation over the coming months and years. The strength of Wolfe’s integrated services presents multiple avenues for achieving growth, and I look forward to leading that process.”

Previously, Oakley was a corporate finance and transactional partner at Sullivan & Worcester, one of the leading private law firms headquartered in Boston, Massachusetts. He advised management teams and corporate boards on a wide variety of matters, such as financial strategies and legal precedence, in a range of industries including software, telecommunications, information technology, life sciences, medical devices, energy and clean tech. He began his legal career as an associate at firms in New York City and Washington, D.C. Prior to practicing law, Oakley held communications positions in advertising and public relations, and also as a reporter.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing